Background French national health care insurance system database has suggested 1–3
years use of glucagon like peptide-1 receptor agonists (GLP1RA)(exenatide, liraglutide and …

Background and aims No meta-analysis has analysed the safety and efficacy of
lobeglitazone in type-2 diabetes (T2DM). We undertook this meta-analysis to address this …

Background: Till date, there is no Cochrane meta-analysis available which has analyzed
efficacy and safety of tirzepatide in type-2 diabetes. This meta-analysis was undertaken to …

Aims This study evaluated the efficacy and safety of enavogliflozin, a novel sodium-glucose
cotransporter 2 inhibitor, versus dapagliflozin in Korean patients with type 2 diabetes …

Background A significant number of patients face the issue of weight gain (WG) or
inadequate weight loss (IWL) post-bariatric surgery for obesity. Several studies have been …

The efficacy and safety of medications can be affected by alterations in gut microbiota in
human beings. Among antidiabetic medications, incretin-based therapy such as dipeptidyl …

Background and aim There are efficacy and safety concerns related to teneligliptin
treatment. A systematic review of randomized controlled trials (RCTs) was undertaken to …

Objective Scant data is available on the efficacy and safety of proprotein convertase
subtilisin/kexin type-9 inhibitors (PCSK9i) for early and rapid reduction of low-density …

Background Orforglipron is a novel once‐daily oral non‐peptide glucagon‐like peptide‐1
receptor agonist with several recently published randomized controlled trials (RCTs) …

Objective Scant data is available on the efficacy and safety of adding ezetimibe to high-
intensity statin therapy for early and rapid reduction of low-density lipoprotein cholesterol …